Abstract
IN BRIEF
Type 2 diabetes is a progressive disease in which b[beta symbol]-cell function continually declines and eventually fails, ultimately requiring nearly all patients to be placed on insulin therapy. An increasing body of evidence suggests that early intensive glycemic control reduces long-term vascular outcomes and potentially may prolong b[beta symbol]-cell lifespan and function. Herein, evidence in favor of early insulin therapy on disease progression and long-term outcomes will be reviewed and placed into clinical context.
Publisher
American Diabetes Association
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference50 articles.
1. World Health Organization
: What is diabetes? [article online] Available from http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed 19 March 2009
2. National Institutes of Health
: National diabetes statistics 2007—prevalence of diagnosed and undiagnosed diabetes in the United States, all ages, 2007 [article online]. Available from http://diabetes.niddk.nih.gov/dm/pubs/statistics/#allages. Accessed 19 March 2009
3. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee;Lloyd-Jones;Circulation,2009
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33);U.K. Prospective Diabetes Study Group;Lancet,1998
5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus;DCCT Research Group;N Engl J Med,1993
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献